CFTR and risk of pulmonary arterial hypertension: a case report and mendelian randomization study
j. liao (Guangzhou, China), W. He (Guangzhou, China), Y. Chen (Guangzhou, China), Y. Hu (Xianyang, China), Y. Ning (Guangzhou, China), K. Yang (Guangzhou, China), J. Wang (Guangzhou, China)
Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension
Session: Experimental approaches to pulmonary hypertension
Session type: E-poster session
Number: 1477
Disease area: Pulmonary vascular diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
j. liao (Guangzhou, China), W. He (Guangzhou, China), Y. Chen (Guangzhou, China), Y. Hu (Xianyang, China), Y. Ning (Guangzhou, China), K. Yang (Guangzhou, China), J. Wang (Guangzhou, China). CFTR and risk of pulmonary arterial hypertension: a case report and mendelian randomization study. 1477
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Inflammation biomarkers and risk of pulmonary hypertension: a Mendelian randomization study Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension Year: 2020
Correspondence regarding “T-box protein 4 mutation causing pulmonary arterial hypertension and lung disease”: a single-centre case series Source: Eur Respir J, 55 (5) 1902272; 10.1183/13993003.02272-2019 Year: 2020
Pulmonary arterial hypertension related with congenital heart disease (PAH r-CHD): a retrospective study of 21 patients Source: Annual Congress 2009 - Pulmonary circulation Year: 2009
Observational retrospective study on the treatment of pulmonary hypertension (PH) associated to pulmonary disease in patient with PH out of proportion Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013
Prevalence of pulmonary hypertension in pulmonary sarcoidosis: the first large European prospective study Source: Eur Respir J, 54 (4) 1900897; 10.1183/13993003.00897-2019 Year: 2019
Gut microbiota and pulmonary hypertension:a Mendelian randomization study Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020
Pulmonary arterial hypertension (PAH) in primary Sjögren‘s syndrome: report of 9 cases Source: Eur Respir J 2007; 30: Suppl. 51, 344s Year: 2007
Prevalence of pulmonary arterial hypertension in idiopathic pulmonary fibrosis: a multicenter study Source: Eur Respir J 2007; 30: Suppl. 51, 119s Year: 2007
Is pulmonary arterial hypertension associated with interferon-ß therapy for multiple sclerosis reversible? A case study to explore the complexity Source: ERJ Open Res, 6 (1) 00328-2019; 10.1183/23120541.00328-2019 Year: 2020
Pulmonary hypertension and pulmonary vascular disease: course report Source: Breathe, 14 (1) e4; 10.1183/20734735.019917 Year: 2018
The French registry of pulmonary arterial hypertension in children: characteristics at diagnosis Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension Year: 2007
Severe pulmonary hypertension after the discovery of the familial primary pulmonary hypertension gene Source: Eur Respir J 2001; 17: 1065-1069 Year: 2001
COVID-19 in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a reference centre survey Source: ERJ Open Res, 6 (4) 00520-2020; 10.1183/23120541.00520-2020 Year: 2020
An epidemiological study of pulmonary arterial hypertension Source: Eur Respir J 2007; 30: 104-109 Year: 2007
Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015
The study of risk in pulmonary arterial hypertension Source: Eur Respir Rev 2012 21:234-238 Year: 2012
Metformin added to bosentan therapy in patients with pulmonary arterial hypertension associated with congenital heart defects: a pilot study Source: ERJ Open Res, 4 (3) 00060-2018; 10.1183/23120541.00060-2018 Year: 2018
Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study Source: Eur Respir J, 50 (1) 1700217; 10.1183/13993003.00217-2017 Year: 2017
Pulmonary arterial hypertension associated with exposure to fenfluramine: a report of 109 cases Source: Annual Congress 2007 - Pulmonary hypertension in the clinic Year: 2007